Summary of New Wei Medical Conference Call Company Overview - **Company**: New Wei Medical - **Industry**: Medical Devices, specifically focusing on brain-computer interface (BCI) technology and drug balloon stents Key Points and Arguments Brain-Computer Interface (BCI) Development - New Wei Medical plans to obtain the inspection report for its BCI product in Q1 2026 and will communicate clinical plans with hospitals in Q2 2026, aiming for the first patient to undergo implantation in the same year, targeting conditions like ALS and stroke-related limb dysfunction [2][3] - The company is facing regulatory challenges with its BCI product and is engaging with review agencies through a project to ensure smooth approval processes, referencing similar companies' experiences [2][6] - Stroke is the leading cause of disability and death in China, with approximately 3 million new cases annually and over 20 million existing patients, many of whom suffer from limb dysfunction post-treatment [9] Clinical Development Plans - New Wei Medical aims to finalize clinical plans with top hospitals by June 2026, with ethical approvals expected within three months and patient recruitment starting in Q4 2026 [5] - The clinical trial will involve 20 to 30 patients, with follow-up periods of 6 to 12 months to assess safety and efficacy [5][6] Financial Projections - The company expects a revenue growth of 30% to 35% in 2026, projecting total revenue between 520 million to 530 million yuan [4][21] - Mid-term goals include achieving over 1 billion yuan in revenue by 2028, with an operating profit margin exceeding 20% [4][22] Product Pricing and Market Strategy - The invasive implantation cost is approximately 6,000 yuan, with the final product price expected to be between 200,000 to 300,000 yuan, referencing DBS products for pricing strategy [10][17] - New Wei Medical plans to gradually reduce prices to increase market penetration, targeting a significant population of stroke and ALS patients [17] Regulatory and Technical Challenges - The BCI product faces high regulatory scrutiny due to its innovative nature, with ongoing discussions with regulatory bodies to ensure compliance [6][10] - The company has validated the safety and signal transmission stability of its technology through animal trials, with plans for human trials in 2026 [3] Research and Development - The BCI product consists of a domestically produced electrode stent and an internationally sourced signal processing unit, with ongoing collaborations with domestic chip design companies [11][12] - The company has invested several million yuan annually since 2021 into the BCI project, with a dedicated team of over 10 people established for its development [18] Future Investment Directions - New Wei Medical will continue to focus on the neuro-intervention sector, exploring partnerships and acquisitions to enhance its product offerings [19][20] - The company plans to apply for A-share listing in 2026 to improve liquidity and support growth [25] Competitive Positioning - New Wei Medical's drug balloon stent is expected to receive approval by Q4 2026, positioning it as a significant growth driver [24] - The company aims to maintain a competitive edge in the BCI market by leveraging government support and focusing on product innovation [24] Additional Important Information - The company anticipates that the new BCI business will gradually contribute to revenue, although the exact impact will depend on market promotion efforts [21] - New Wei Medical's operational strategy includes maintaining stable management and R&D expenses to support growth [23]